Cameron John Reynolds Buys 181,818 Shares of VolitionRx Limited (NYSE:VNRX) Stock

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds bought 181,818 shares of VolitionRx stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now directly owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

VolitionRx Trading Up 4.9 %

NYSE:VNRX traded up $0.03 on Thursday, reaching $0.54. 117,989 shares of the stock traded hands, compared to its average volume of 177,031. The company’s fifty day simple moving average is $0.59 and its 200 day simple moving average is $0.64. The company has a market capitalization of $50.04 million, a price-to-earnings ratio of -1.50 and a beta of 1.09. VolitionRx Limited has a 12 month low of $0.43 and a 12 month high of $1.02.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on VNRX shares. StockNews.com initiated coverage on shares of VolitionRx in a research note on Thursday, March 20th. They set a “sell” rating for the company. D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research note on Thursday, March 20th.

Institutional Investors Weigh In On VolitionRx

Several large investors have recently bought and sold shares of the business. Two Sigma Securities LLC bought a new stake in shares of VolitionRx in the fourth quarter worth approximately $29,000. Millennium Management LLC bought a new position in VolitionRx during the fourth quarter valued at approximately $36,000. Northern Trust Corp boosted its holdings in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the last quarter. Geode Capital Management LLC grew its position in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.